Navigation Links
Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Soft Tissue Sarcoma and Osteosarcoma: Phase I/II & Confirmatory Phase II Studies
Date:11/20/2008

SAN MARINO, Calif., Nov. 20 /PRNewswire/ -- Epeius Biotechnologies announced today the results of Phase I/II and II studies of Rexin-G in chemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma, as presented by Dr. Sant P. Chawla, principal investigator, at the CTOS 14th annual meetings held in London UK on November 13-15, 2008. Patients received repeated infusions of Rexin-G i.v. over a period up to 9 months. Analysis of safety and efficacy data showed no major toxicity, while documenting significant control of tumor growth.

Analysis of efficacy in 42 patients with bone and soft tissue sarcoma showed a dose-response relationship between overall survival and Rexin-G which was highly significant. A confirmatory Phase II study in 17 osteosarcoma patients showed a median overall survival greater than seven months; that is, after failing standard chemotherapies. Two patients are disease-free greater than 6 months after surgical resection of residual tumors and Rexin-G given as both neoadjuvant and adjuvant monotherapy. These studies indicate that (i) intravenous Rexin-G is safe and well-tolerated, and (ii) Rexin-G controls tumor growth and improves survival in a dose-dependent manner in patients with chemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma.

About Epeius Biotechnologies

Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its proprietary targeted delivery systems. To learn more about Rexin-G and Epeius Biotechnologies' pipeline of proprietary compounds currently available for clinical development, please visit us at http://www.epeiusbiotech.com .

*(LOGO 72dpi: Send2Press.com/mediaboom/08-0421-Epeius_72dpi.jpg)

This release was issued on behalf of the above
'/>"/>

SOURCE Epeius Biotechnologies
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Phase I/II Study of Targeted Gene Delivery In Vivo - Intravenous Infusions of REXIN-G - Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Patients With Progressive Chemo-Resistant Bone and Soft Tissue Sarcoma (ASCO 2008)
2. TARGETED GENE DELIVERY SIGNALS CANCER VACCINATION IN VIVO: Intravenous Infusions of Rexin-G Followed by Reximmune-C Induce Tumor Necrosis and Recruitment of Tumor Infiltrating Lymphocytes in Cancerous Lesions (ASCO 2008)
3. TARGETED GENE DELIVERY IN VIVO: Rexin-G Monotherapy Reveals Significant Biological Activity Without Toxicity in Chemo-Resistant Metastatic Breast Cancer (ASCO 2008)
4. Interim Analysis of Phase I/II Study of Rexin-G Confirms Efficacy With No Dose Limiting Toxicity in Metastatic Pancreatic Cancer
5. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
6. New Insight Into the Controls on a Go-To Enzyme
7. Chemstar Corporation Announces a New Powerful, One-Step Product That Effectively Controls Listeria, Salmonella, E. coli and Fly Larvae in Floor Drains
8. RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors
9. Chipscreen Biosciences and HUYA Bioscience Intl Announce Promising Preclincial and Phase I Solid Tumor/Lymphoma Data for Chidamide/HBI-8000, New HDAC Inhibitor for Cancer
10. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
11. CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014  Publicis Groupe customer engagement agency ... and Healthcare Industry Group Leader, has been featured in ... most inspiring people in the life-sciences industry. Those chosen ... development, marketing, technology, creativity, strategy and medicine. ... partner in its leading Rosetta Consulting practice. In 2012, ...
(Date:8/21/2014)... 21, 2014 /PRNewswire-iReach/ -- Inc. magazine ... the third straight year, No. 349 in Health ... ranking of the nation,s fastest-growing private companies. The ... most important segment of the economy—America,s independent entrepreneurs. ... Pizza, LinkedIn, Zillow, and many other well-known names ...
(Date:8/21/2014)... 21, 2014  Zacks.com announces the list of stocks featured ... analysts discuss the latest news and events impacting stocks and ... Hewlett-Packard (NYSE: HPQ - Free Report ), IBM (NYSE: ... SB - Free Report ), GlaxoSmithKline plc (NYSE: ... FI - Free Report ). Today, Zacks ...
Breaking Medicine Technology:Shannon Hartley Shines in PharmaVOICE 100 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 3The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 2The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 3The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 4The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 5The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 6The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 7The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 8The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 9The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 10The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 11
... Wis., Jan. 10, 2012  With increasing demands for time ... or shuttling the children to and from their many ... challenge. To make life simpler for shoppers always on ... pharmacy app, allowing users to quickly and easily refill ...
... a leading provider of software solutions to optimize clinical ... announced the release of StudyOptimizer 4.4, the latest version ... tracking and forecasting. With new customer-driven ... innovations in StudyOptimizer enable pharmaceutical companies to easily optimize ...
Cached Medicine Technology:Shopko Launches Mobile Pharmacy App to Maximize Customer Convenience 2DecisionView Enhances Market-Leading Clinical Enrollment Optimization Solution With Improved Cost Modeling 2
(Date:8/23/2014)... 23, 2014 Peripheral intervention surgeries are ... plaques, etc, thereby addressing the root cause of peripheral ... blood to the other part of the arteries where ... These procedures require the use of a catheter, (which ... polymers), these catheters are inserted through a thin cut ...
(Date:8/23/2014)... August 23, 2014 Hundreds of ... on behalf of individuals who were allegedly harmed ... line continue to move forward in the U.S. ... LLP reports. According to an Order dated August ... program that would allow the litigation’s first case ...
(Date:8/23/2014)... Boston, MA (PRWEB) August 23, 2014 ... now have a study aid in preparing for Food ... safety practice test by Dynamic Path. , Dynamic ... study module, which includes more than 200 review questions ... study materials are designed to cover requirements of the ...
(Date:8/23/2014)... Teen drug and alcohol abuse is a major ... NC. Substance abuse can happen to people of all ... alcohol dependency in higher numbers than ever before. ... but don’t know where to find professional youth rehab. ... challenge because most treatment options are designed for adults. ...
(Date:8/22/2014)... August 23, 2014 2014 Deep ... a professional and in-depth research report on the ... Meter information, including Glucose Meter definition, classification, application, ... overview. This research covers the international market analysis, ... analysis covering macroeconomic environment & economic situation analysis. ...
Breaking Medicine News(10 mins):Health News:Global Peripheral Intervention Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Health News:Global Peripheral Intervention Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Health News:Global Peripheral Intervention Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4Health News:Wright Conserve Hip Lawsuits Move Forward, as Federal Court Issues Order Pertaining to Bellwether Trials, Bernstein Liebhard LLP Reports 2Health News:Wright Conserve Hip Lawsuits Move Forward, as Federal Court Issues Order Pertaining to Bellwether Trials, Bernstein Liebhard LLP Reports 3Health News:Wright Conserve Hip Lawsuits Move Forward, as Federal Court Issues Order Pertaining to Bellwether Trials, Bernstein Liebhard LLP Reports 4Health News:Food Handler Safety Certification Made Easy with Dynamic Path 2Health News:Troubled Teens Wilmington Helpline Guides Adolescents to the Path of Recovery 2Health News:Glucose Meter Industry Global (Europe, Asia, NA, ROW) Analysis Now Available at ReportsnReports.com 2Health News:Glucose Meter Industry Global (Europe, Asia, NA, ROW) Analysis Now Available at ReportsnReports.com 3
... Speaker Nancy Pelosi,Senate Majority Leader Harry Reid and ... USA, Easter Seals, and other advocates at a,news conference ... the,President,s veto of the Children,s Health Insurance Program. Below ... Families USA, to Easter Seals, and to the,representatives of ...
... race to the 2008 elections,heats up, nearly every presidential ... "But when it comes to the already deteriorating ... industry players is a more,overarching consideration than the rhetoric ... & Poor,s Ratings Services,in a report published Oct. 12, ...
... VICTORIA, Oct. 16 /PRNewswire-FirstCall/ - Aspreva Pharmaceuticals,Corporation (NASDAQ: ... and,unaudited net revenues of approximately US $62 million ... $47.9 million revenue in the third quarter,of 2006. ... full financial,results on Wednesday, October 31, 2007. The ...
... Genzyme Corporation,(Nasdaq: GENZ ) today participated in ... during which the committee voted 8 to,4, with ... the indications,for phosphate binders to use in pre-dialysis ... the most,prescribed phosphate binder in the United States, ...
... Oct. 16 The Cambridge Group, a leading,strategy ... Shea,principals of the firm. Mr. Miller brings ... experience to The Cambridge Group. In his career, ... in senior,executive and consulting positions. In his most ...
... Corporation (Pink,Sheets: MNCN) is proud to announce that it ... Commission. The company had announced,previously its intention of becoming ... made it official. The company is next filing to ... SB-2. "This is a,monumental day for Mach One; we ...
Cached Medicine News:Health News:Pelosi: In 48 Hours, Congress Must Choose Between Meeting the Needs of America's Children or Not 2Health News:S&P: Leverage Tops Politics as Primary Credit Concern for U.S. Health Care Companies, Says S&P 2Health News:Aspreva Announces Preliminary Revenues for Third Quarter 2007 2Health News:Aspreva Announces Preliminary Revenues for Third Quarter 2007 3Health News:Aspreva Announces Preliminary Revenues for Third Quarter 2007 4Health News:Genzyme Statement Regarding Results of FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease 2Health News:Genzyme Statement Regarding Results of FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease 3Health News:The Cambridge Group Names Two New Principals 2Health News:Mach One Corporation Files its Form SB-2 with the SEC 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: